02393 YESTAR HEALTH
- 0.042
- -0.001-2.33%
YESTAR HEALTH News
Yestar Healthcare Narrows Loss in 2023
Yestar Healthcare Holdings (HKG:2393) reported an attributable loss of 13.9 million yuan for the year ended Dec. 31, 2023, compared with a loss of 992.2 million yuan in the previous year, according to
巨星醫療控股：年度報告 2023
Yestar Healthcare Faces Second Arbitration Related to Trading Firm Acquisition
Yestar Healthcare Holdings (HKG:2393) received a notice of a second arbitration related to its acquisition of a 70% stake in Guangzhou Shengshiyuan Trading, according to a filing with the Hong Kong Ex
Superstar Healthcare Holdings (02393): Leung Chun-hung resigns as executive director
Superstar Medical Holdings (02393) announced that Leung Chun-hung undertakes other duties related to his future career and business development...
Superstar Medical Holdings (02393) announced annual results. Losses attributable to shareholders of 13.888 million yuan narrowed 98.6% year-on-year
According to the Zhitong Finance App, Superstar Medical Holdings (02393) announced its annual results for the year ended December 31, 2023. The group achieved continuous business revenue of 2,913 billion yuan (RMB, same below) during the period, an increase of 3.86% over the previous year; losses attributable to shareholders were 13.888 million yuan, a year-on-year decrease of 98.6%; and a basic loss of 0.6 points per share. According to the announcement, demand for the Group's in vitro diagnostic consumables increased in 2023, mainly due to a sharp rise in demand for cardiomyocardial products from patients with diseases caused by COVID-19 in the first quarter of 2023. Receipts from continuing operations in this segment
YESTAR HEALTH: ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Superstar Medical Holdings (02393.HK) expects net loss of not more than 10 million yuan in fiscal year 2023
Gelonghui, March 15, 丨 Superstar Medical Holdings (02393.HK) announced that compared to the Group's audited net loss of approximately RMB 1.02 billion for the year ended December 31, 2022, the Group expects a sharp reduction in fiscal year 2023 and recorded a net loss of not more than RMB 10 million. The Group expects a sharp decrease in net losses in fiscal year 2023 mainly due to (i) a sharp reduction in impairment losses on goodwill and other intangible assets in fiscal year 2023; (ii) impairment losses on the return of some financial assets; and (iii) a sharp drop in financial costs.
YESTAR HEALTH: PROFIT WARNING
Superstar Healthcare Holdings (02393.HK) held a board meeting on March 27 to consider and approve the annual results
Glonghui, March 15, 丨 Superstar Healthcare Holdings (02393.HK) announced that the company will hold a board meeting on March 27, 2024 (Wednesday) to consider and approve (among other things) the annual results of the company and its subsidiaries for the year ended December 31, 2023, and to recommend payment of a final dividend (if any).
YESTAR HEALTH: DATE OF BOARD MEETING
Superstar Healthcare Holdings will redeem US$198 million 9.5% senior notes due in 2026
Superstar Medical Holdings (02393) announced that the company is known to be a trustee. On March 13, 2024 (redemption date), the company will pay the redemption amount to redeem all outstanding notes (US$198 million 9.5% senior notes due in 2026) along with related unpaid interest payments.
Superstar Medical Holdings (02393) will redeem US$198 million 9.5% senior notes due in 2026
Superstar Medical Holdings (02393) announced that the company is known to be a trustee on March 13, 2024 (redemption...
Superstar Medical Holdings (02393) received the original written arbitration award and was required to pay the applicant a share transfer of $22.54 million
Zhitong Finance App News, Superstar Medical Holdings (02393) issued an announcement containing the latest news on the profit guarantee for the acquisition of 70% equity interest in Guangzhou Shengshiyuan Trading Co., Ltd., one of Sheng Shiyuan's sellers (holding 6% interest in Shengshiyuan) (the applicant) requested the company to acquire the relevant share capital rights related to 30% of Shengshiyuan's share capital interest at a cost of about RMB 225.42 million, and claimed from the company RMB 9.0899 million (provisional until May 10, 2023). The arbitral tribunal commenced in November 2023
Superstar Medical Holdings (02393): The proposed debt repayment plan has been approved by the required majority of the plan's creditors
According to the Zhitong Finance App, Superstar Healthcare Holdings (02393) announced that the planned creditors' meeting held at the office of Dejie Law Firm on the 31st floor of Jardine Building, 1 Connaught Place, Central, Hong Kong will begin at 8:02 p.m. on February 19, 2024, Hong Kong time. At the meeting, a total of 124 plan creditors participated in the planning meeting. Among them, 124 plan creditors voted in favor of the proposed debt repayment plan. As a result, the plan has been approved by the required majority of plan creditors. The plan will then be subject to court approval and approval. The company hereby announces that it will seek a court appointment in Cayman Islands Time2
Superstar Healthcare Holdings [02393] now reports HK$0.028, a decrease of 17.65%
As of 09:45, Superstar Medical Holdings [02393] reported HK$0.028, down HK$0.006 or 17.65% from yesterday's closing price, with a turnover of HK$34,500. Today's high price was HK$0.031 and the lowest price was HK$0.028. Based on yesterday's closing price, the 10-day average price was HK$0.02 and the 50-day average price was HK$0.08. The current price-earnings ratio was -0.07 times, and the 14-day strength and weakness index was reported at 61.76.
Superstar Healthcare Holdings [02393] now reports HK$0.031, a decrease of 16.22%
As of 15:49, Superstar Healthcare Holdings [02393] reported HK$0.031, down HK$0.006 or 16.22% from yesterday's closing price, with a turnover of HK$754,700. Today's high price was HK$0.045, and the lowest price was HK$0.031. Based on yesterday's closing price, the 10-day average price was HK$0.02, and the 50-day average price was HK$0.08.
Superstar Medical Holdings [02393] now reports HK$0.041, an increase of 10.81%
As of 09:30, Superstar Healthcare Holdings [02393] reported HK$0.041, up HK$0.004 or 10.81% from yesterday's closing price, with a turnover of HK$19,600, today's high of HK$0.041 and a low price of HK$0.04. Based on yesterday's closing price, the 10-day average price was HK$0.02, and the 50-day average price was HK$0.08.
Superstar Healthcare Holdings [02393] now reports HK$0.023, an increase of 15.00%
As of 10:27, Superstar Healthcare Holdings [02393] reported HK$0.023, up HK$0.003 or 15.00% from yesterday's closing price, with a turnover of HK$61,500. Today's high price was HK$0.023, and the lowest price was HK$0.02. Based on yesterday's closing price, the 10-day average price was HK$0.02, and the 50-day average price was HK$0.08. The current price-earnings ratio was -0.04 times, and the 14-day strength and weakness index reported 26.67.
Yestar Healthcare to Host Creditors Meeting for Debt Restructuring Scheme on Feb. 19
Yestar Healthcare Holdings (HKG:2393) provided an update on its offshore debt restructuring scheme, saying the Grand Court of the Cayman Islands has directed the firm to convene a meeting with the scheme creditors.
Yestar Healthcare Completes Disposal of Group of Companies; Shares Up 3%
Yestar Healthcare Holdings (HKG:2393) completed the disposal of a group of companies. The medical consumables and equipment company's subsidiary, Yestar Medical, sold 94.2% in each of Shanghai Emphasi
Analysis
Price Target
No Data
